In the BioHarmony Drug Report Database
Cabotegravir
Vocabria (cabotegravir) is a small molecule pharmaceutical. Cabotegravir was first approved as Vocabria on 2020-12-17. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Cabenuva’s patent is valid until 2026-04-28 (FDA).
Trade Name
|
Vocabria |
|---|---|
Common Name
|
cabotegravir |
ChEMBL ID
|
CHEMBL2403238 |
Indication
|
hiv infections |
Drug Class
|
Antivirals: integrase inhibitors |
Image (chem structure or protein)